J2350 HCPCS code: Injection, ocrelizumab, 1 mg
J2350 is the HCPCS Level II code for injection, ocrelizumab, 1 mg. In 2024 Medicare paid an average of $42.96 per service for J2350 across 4,887,519 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 600 per day on outpatient hospital claims. Medicare volume rose 2% from 2022 to 2024 (4,804,208 to 4,887,519 services). In 2024, about 1,903 clinicians billed Medicare for J2350 for 5,160 beneficiaries; Florida, Texas, New York accounted for 28% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2018-01-01 |
| Last action effective | 2018-01-01 |
Who bills J2350 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,903 |
| Medicare beneficiaries | 5,160 |
| States with claims | 42 |
| Share of services in top 3 states (Florida, Texas, New York) | 28% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J2350, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 4,804,208 | 5,154 | $53.98 | $43.12 |
| 2023 | 4,955,709 | 5,220 | $54.22 | $43.22 |
| 2024 | 4,887,519 | 5,160 | $53.90 | $42.96 |
States with the most J2350 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 570,186 | $44.18 |
| Texas | 403,837 | $39.75 |
| New York | 368,666 | $44.59 |
| California | 260,392 | $45.39 |
| Maryland | 240,349 | $44.90 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 600 | Prescribing Information |
| practitioner claims | 600 | Prescribing Information |
What changed for J2350
- 2018-01-01: J2350 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2350?
J2350 is the HCPCS Level II code for injection, ocrelizumab, 1 mg. Short descriptor: "Injection, ocrelizumab, 1 mg".
How much does Medicare pay for J2350?
In 2024, the average Medicare payment was $42.96 per service (average allowed $53.90).
Does Medicare cover J2350?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J2350 can be billed per day?
600 on outpatient hospital claims; 600 on practitioner claims (NCCI medically unlikely edits).
Related J23 codes
- J2300 — Injection, nalbuphine hydrochloride, per 10 mg
- J2305 — Injection, nitroglycerin, 5 mg
- J2310 — Injection, naloxone hydrochloride, per 1 mg
- J2311 — Injection, naloxone hydrochloride (zimhi), 1 mg
- J2312 — Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313 — Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315 — Injection, naltrexone, depot form, 1 mg
- J2320 — Injection, nandrolone decanoate, up to 50 mg
- J2323 — Injection, natalizumab, 1 mg
- J2325 — Injection, nesiritide, 0.1 mg
- J2326 — Injection, nusinersen, 0.1 mg
- J2327 — Injection, risankizumab-rzaa, intravenous, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2350
- Watch J2350 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2350
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.